Thomassen, Anders by unknown
Syddansk Universitet
Thoracic aorta calcification but not inflammation is associated with increased
cardiovascular disease risk
Blomberg, Björn Alexander; de Jong, Pim A; Thomassen, Anders; Lam, Marnix G E; Vach,
Werner; Olsen, Michael Hecht; Mali, Willem P T M; Narula, Jagat; Alavi, Abass; Høilund-
Carlsen, Poul Flemming
Published in:
European Journal of Nuclear Medicine and Molecular Imaging
DOI:
10.1007/s00259-016-3552-9
Publication date:
2016
Document Version
Final published version
Link to publication
Citation for pulished version (APA):
Blomberg, B. A., de Jong, P. A., Thomassen, A., Lam, M. G. E., Vach, W., Olsen, M. H., ... Høilund-Carlsen, P.
F. (2016). Thoracic aorta calcification but not inflammation is associated with increased cardiovascular disease
risk: results of the CAMONA study. European Journal of Nuclear Medicine and Molecular Imaging, 44(2),
249–258. DOI: 10.1007/s00259-016-3552-9
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 17. jan.. 2017
ORIGINAL ARTICLE
Thoracic aorta calcification but not inflammation
is associated with increased cardiovascular disease risk:
results of the CAMONA study
Björn A. Blomberg1,2 & Pim A. de Jong2 & Anders Thomassen1 & Marnix G. E. Lam2 &
Werner Vach3 & Michael H. Olsen4 & Willem P. T. M. Mali2 & Jagat Narula5 &
Abass Alavi6 & Poul F. Høilund-Carlsen1,7
Received: 15 April 2016 /Accepted: 11 October 2016 /Published online: 29 October 2016
# The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract
Purpose Arterial inflammation and vascular calcification are
regarded as early prognostic markers of cardiovascular disease
(CVD). In this study we investigated the relationship between
CVD risk and arterial inflammation (18F-FDG PET/CT imag-
ing), vascular calcification metabolism (Na18F PET/CT imag-
ing), and vascular calcium burden (CT imaging) of the thorac-
ic aorta in a population at low CVD risk.
Methods Study participants underwent blood pressure mea-
surements, blood analyses, and 18F-FDG and Na18F PET/CT
imaging. In addition, the 10-year risk for development of
CVD, based on the Framingham risk score (FRS), was
estimated. CVD risk was compared across quartiles of thorac-
ic aorta 18F-FDG uptake, Na18F uptake, and calcium burden
on CT.
Results A total of 139 subjects (52%men, mean age 49 years,
age range 21 – 75 years, median FRS 6 %) were evaluated.
CVD risk was, on average, 3.7 times higher among subjects
with thoracic aorta Na18F uptake in the highest quartile com-
pared with those in the lowest quartile of the distribution
(15.5 % vs. 4.2 %; P < 0.001). CVD risk was on average,
3.7 times higher among subjects with a thoracic aorta calcium
burden on CT in the highest quartile compared with those in
the lowest two quartiles of the distribution (18.0 % vs. 4.9 %;
P < 0.001). CVD risk was similar in subjects in all quartiles of
thoracic aorta 18F-FDG uptake.
Conclusion Our findings indicate that an unfavourable CVD
risk profile is associated with marked increases in vascular
calcification metabolism and vascular calcium burden of the
thoracic aorta, but not with arterial inflammation.
Keywords PET/CT . [18F]Fluorodeoxyglucose (18F-FDG) .
[18F]Sodium fluoride (Na18F) . Arterial inflammation .
Vascular calcification . Atherosclerosis
Introduction
Adverse cardiovascular events and their sequelae are a major
health concern in Western societies [1]. Efforts to prevent
adverse cardiovascular events have focused on identifying
asymptomatic individuals at high risk of cardiovascular dis-
ease (CVD), the so-called Bvulnerable^ patient [2, 3]. In the-
ory, vulnerable patients benefit most from intensive evidence-
based medical interventions. However, identifying the vulner-
able patient remains a major ongoing challenge [2].
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Recent developments in cardiovascular imaging, aimed at
visualizing key pathophysiological processes in CVD, offer
new opportunities for assessing patient vulnerability.
Amongst others, arterial inflammation [4] and vascular calci-
fication [5] have received attention as potent markers of in-
creased CVD risk [6–8]. 18F-FDG PET/CT imaging can non-
invasively assess arterial inflammation, whereas Na18F PET/
CT and CT imaging can noninvasively assess vascular calci-
fication (Fig. 1).
Although CVD risk in relation to arterial inflammation (18F-
FDG PET/CT imaging), vascular calcification metabolism
(Na18F PET/CT imaging), and vascular calcium burden (CT im-
aging) has been previously studied, in only a limited number of
studies a combined approach has been applied [9, 10].Moreover,
few investigations have evaluated these cardiovascular imaging
modalities in relation to CVD risk in a population at low CVD
risk. Therefore, the aim of this study was to evaluate the relation-
ship between CVD risk and arterial inflammation, vascular cal-
cificationmetabolism, and vascular calcium burden in a cohort of
subjects at lowCVD risk, namely healthy volunteers and patients
evaluated for chest pain syndromes.
Materials and methods
This study was part of the BCardiovascular Molecular
Calcification Assessed by 18F-NaF PET/CT^ (CAMONA)
study. The CAMONA study was approved by the Danish
National Committee on Health Research Ethics, registered at
ClinicalTrials.gov (NCT01724749), and conducted in accor-
dance with the principles of the Declaration of Helsinki. All
study participants provided written informed consent.
Subject selection
We recruited a heterogeneous population of subjects, in-
cluding healthy volunteers and patients evaluated for
chest pain syndromes. This allowed us to study the rela-
tionship between CVD risk and arterial inflammation,
vascular calcification metabolism, and vascular calcium
burden in a heterogeneous, but clinically relevant, group
of subjects regarded to be at low CVD risk. Healthy vol-
unteers were recruited from the general population by lo-
cal advertisement or from the blood bank of Odense
University Hospital, Denmark. Volunteers free of onco-
logical disease, autoimmune disease, immunodeficiency
syndromes, alcohol abuse, illicit drug use, (symptoms
suggesting) CVD, or any prescription medication were
considered healthy and were eligible for inclusion.
Patients evaluated for chest pain syndromes were recruit-
ed from those referred for coronary CT angiography. Only
patients with a 10-year risk of fatal CVD equal to or
above 1 %, as estimated by the body mass index based
the Systematic Coronary Risk Evaluation tool [11], were
eligible for inclusion. Pregnant women were not consid-
ered for inclusion.
Fig. 1 Axial CT (a, c), 18F-FDG
PET/CT (b), and Na18F PET/CT
(d) images obtained at the same
location in 69-year-old man with
hypertension, a body mass index
of 28 kg/m2, and a Framingham
risk score of 26 %. 18F-FDG ac-
cumulation is seen in the de-
scending thoracic aorta (b white
arrowheads), but not at sites with
structural calcium deposits (a, c
black arrowheads). In the Na18F
PET/CT image (d) active (white
arrowhead) and indolent (black
arrowhead) vascular calcifica-
tions are distinguished
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Study design
Study participants were evaluated by questionnaires, blood
pressure measurements, blood analyses, the Framingham risk
score (FRS) [12], 18F-FDG PET/CT imaging, and Na18F PET/
CT imaging. In addition, body weight and body mass index
were determined. Questionnaires collected information about
smoking habits, family history of CVD, and prescription med-
ication. Blood pressure was measured three times after the
subject had rested for of at least 30 min in the supine position.
The average of the last two measurements was taken as the
systolic and diastolic blood pressure. Blood analyses included
fasting serum total cholesterol, serum LDL cholesterol, serum
HDL cholesterol, serum triglycerides, fasting plasma glucose
and glycated haemoglobin (HbA1c), and the Modification of
Diet and Renal Disease (MDRD) equation was used to esti-
mate glomerular filtration rate. In each subject, the 10-year
risk of developing CVDwas estimated using the FRS (i.e. risk
of coronary death, myocardial infarction, coronary insuffi-
ciency, angina, ischaemic stroke, haemorrhagic stroke, tran-
sient ischaemic attack, peripheral artery disease, heart failure)
based on age, gender, systolic blood pressure, total serum
cholesterol, serum HDL cholesterol, smoking habit, and treat-
ment for hypertension [12].
18F-FDG and Na18F PET/CT imaging were performed
according to previously published methods [13, 14]. In sum-
mary, 18F-FDG and Na18F PET/CT imaging were performed
on hybrid PET/CT systems (GE Discovery STE, VCT, RX,
and 690/710 systems). Subjects were randomly allocated to a
PET/CTsystem by the department’s booking system. PET/CT
system specifications and image reconstruction parameters are
summarized in Supplementary Table 1. 18F-FDG PET/CT im-
aging was performed 180 min after intravenous injection of
4.0 MBq of 18F-FDG per kilogram of body weight [13]. 18F-
FDG was administered after an overnight fast of at least 8 h.
Before 18F-FDG injection, the blood glucose concentration
was determined to ensure a value below 8 mmol/L. On aver-
age, Na18F PET/CT imaging was performedwithin 2 weeks of
18F-FDG PET/CT imaging. Na18F PET/CT imaging was per-
formed 90 min after intravenous injection of 2.2 MBq of
Na18F per kilogram of body weight [14]. PET images were
corrected for attenuation, scatter, random coincidences, and
scanner dead time. Low–dose CT imaging (140 kV,
30 – 110mA, noise index 25, 0.8 s per rotation, slice thickness
3.75 mm) was performed for attenuation correction, for ana-
tomical orientation, and to determine the thoracic aorta CT
calcium burden. The effective radiation dose received from
the entire imaging protocol was approximately 14 mSv.
Quantitative image analyses
All images were analysed using Philips IntelliSpace Portal
Client, version 4.0. The image analyst was masked to the
subject’s demographics and to the image specifications.
Arterial 18F-FDG andNa18F uptakewere quantified according
to previously published methods [13–15]. In summary, uptake
of 18F-FDG in the thoracic aorta was determined by manually
placing an oval region of interest (ROI) around the outer pe-
rimeter of the artery on every slice of the axially oriented PET/
CT images. For each ROI, the maximum decay-corrected 18F-
FDG activity concentration was calculated. The maximum
values obtained for each ROI were summed and divided by
the number of ROIs, resulting in a single averaged maximum
value (FDGMAX). Thoracic aorta NaFMAX values were calcu-
lated in a similar manner. Blood 18F-FDG activity and blood
Na18F activity were determined by drawing a single ROI in
the lumen of the superior vena cava. Blood 18F-FDG activity
and blood Na18F activity were quantified as the decay-
corrected mean radiotracer activity concentration. Finally,
the thoracic aorta CT calcium burden was calculated.
The CT calcium burden was determined on low-dose CT
images obtained as part of PET/CT imaging by calculating the
calcium volume on every slice of the axially oriented CT
images. Volumes obtained in each slice were summed and
divided by the number of slices, resulting in a single mean
CT calcium volume. The detection threshold for vascular cal-
cium was set at 130 HU. The agreement between mean calci-
um volumes calculated on CT images from 18F-FDG PET/CT
and those calculated from Na18F PET/CT was found to be
excellent, and the CT images from 18F-FDG PET/CT were
therefore used as reference for the statistical analysis. We
could not assess interscan agreement for FDGMAX and
NaFMAX because the
18F-FDG PET/CT and Na18F PET/CT
scans were acquired only once.
Statistical analysis
First, FDGMAX and NaFMAX were adjusted for blood activity,
injected dose and PET/CT technology by multivariable linear
regression, because previous studies had indicated that these
parameters significantly affect the quantification of arterial
18F-FDG and Na18F uptake [15, 16]. Second, subject demo-
graphics are summarized by descriptive statistics and com-
pared between healthy volunteers and patients using the un-
paired Student’s t test, the Mann-Whitney U test, or Fisher’s
exact test. Third, the correlations among thoracic aorta
FDGMAX, thoracic aorta NaFMAX and thoracic aorta CT cal-
cium burden, were evaluated in terms of Spearman’s rank
correlation coefficient (ρ). Fourth, the associations between
cardiovascular risk factors and thoracic aorta FDGMAX,
NaFMAX and CTcalcium burden were evaluated by univariate
regression analysis, and those that were significantly associat-
ed were adjusted for age and sex. Linear models were extend-
ed by interaction terms to determine if the associations be-
tween cardiovascular risk factors and FDGMAX, NaFMAX
and CT calcium burden were modified by sex, subject
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recruitment (i.e. volunteers vs. patients), or prescription med-
ication. Because no significant interactions were observed,
results were not separated in relation to sex, volunteers/pa-
tients, or prescription medication. To establish independent
determinants of thoracic aorta FDGMAX, NaFMAX, and CT
calcium burden, variables selected on the basis of the results
of the univariate analysis were entered into a multivariable
linear regression analysis.
The 10-year risks of CVD based on FRS were then esti-
mated and these risk estimates were compared across quartiles
of FDGMAX, NaFMAX and CT calcium burden using factorial
analysis of covariance (ANCOVA). The relationships between
FRS and FDGMAX, NaFMAX and CT calcium burden were
also evaluated continuously using Spearman’s ρ and by mul-
tivariable linear regression analysis. All statistical analyses
were repeated replacing FDGMAX and NaFMAX with the ratios
of the maximum tracer activity in the aortic wall to the mean
activity in the blood pool (target-to-background ratios, TBR)
for 18F-FDG and Na18F (FDG-TBRMAX/MEAN and NaF-
TBRMAX/MEAN, respectively). TBR is commonly used to ex-
press aortic FDG and NaF uptake, but its use has been criti-
cized [15, 16]. The results of these analyses are reported in
Supplementary Fig. 2 and Supplementary Tables 5–7). Lastly,
we assessed the agreement between the mean CT calcium
volumes calculated on CT images from 18F-FDG PET/CT
and those calculated on images from Na18F PET/CT in terms
of the 95 % limits of agreement according to the method of
Bland and Altman [17]. A two-tailed P value below 0.05 was
regarded statistically significant. P values and 95 % confi-
dence intervals were determined by a bootstrap of 2,000 sam-
ples. Statistical analyses were performed using SPSS
Statistics, version 21 (IBM Corp., Armonk NY).
Results
Between November 2012 and May 2014 89 healthy vol-
unteers and 50 patients evaluated for chest pain syn-
dromes were prospectively recruited. Several differences
in subject demographics were observed between volun-
teers and patients (Table 1). These differences were main-
ly related to age, except for smoking habit, family history,
HbA1c, FRS, and prescription medication, which
remained significantly higher among patients compared
with volunteers after adjustment for age. The ages of the
study population ranged from 21 – 75 years and FRS
ranged from 0.3 – 30.0 %.
Thoracic aorta 18F-FDG uptake was not correlated with
either thoracic aorta Na18F uptake or thoracic aorta CT calci-
um burden, whereas thoracic aorta Na18F uptake was positive-
ly correlated with thoracic aorta CT calcium burden
(Spearman’s ρ = 0.42, P < 0.001; Fig. 2).
The results of the univariate analysis are presented in
Supplementary Tables 2–4. The multivariable linear re-
gression analysis showed that independent determinants
of thoracic aorta 18F-FDG uptake were subject age
(0.41 kBq/mL per SD, P = 0.008) and family history
(0.66 kBq/mL, P = 0.035), which explained an additional
4 % of the variation in thoracic aorta FDGMAX (adjusted
R2 increased from 0.60 to 0.64, P = 0.001). Blood 18F-
FDG activity, injected 18F-FDG dose and PET/CT tech-
nology explained the initial 60 % of the variation in the
data. The multivariable linear regression analysis showed
that independent determinants of thoracic aorta Na18F up-
take were subject age (0.25 kBq/mL per SD, P < 0.001),
body mass index (0.12 kBq/mL per SD, P = 0.017), renal
function (−0.09 kBq/mL per SD, P = 0.022) and thoracic
aorta CT calcium burden (0.08 kBq/mL per SD, P =
0.002), which explained an additional 9 % of the variation
in thoracic aorta NaFMAX (adjusted R
2 increased from
0.71 to 0.80, P < 0.001). Blood Na18F activity, injected
Na18F dose and PET/CT technology explained the initial
71 % of the variation in the data. The multivariable linear
regression showed that independent determinants of thoracic aor-
ta CT calcium burden were subject age (1.47 mm3 per SD, P =
0.013) and antihypertensive treatment (10.17 mm3, P = 0.030),
which explained 28% of the variation in thoracic aorta mean CT
calcium volume (adjusted R2 = 0.28, P < 0.001).
FRS was similar in all quartiles of thoracic aorta 18F-FDG
uptake (P = 0.492 for a linear trend, Spearman’s ρ = 0.12; P =
0.156). In contrast, FRS increased linearly with each increas-
ing quartile of thoracic aorta Na18F uptake (P < 0.001 for a
linear trend, Spearman’s ρ = 0.50; P < 0.001). FRS was on
average 3.7 times higher in subjects with thoracic aorta
Na18F uptake in the highest quartile compared with those in
the lowest quartile of the distribution (15.5 % vs. 4.2 %;
P < 0.001). FRS also increased linearly in subjects with in-
creasing quartiles of thoracic aorta CT calcium burden
(P < 0.001 for a linear trend, Spearman’s ρ = 0.63;
P < 0.001). FRS was on average 3.7 times higher among sub-
jects with thoracic aorta CT calcium burden in the highest
quartile compared with those in the lowest two quartiles of
the distribution (18.0 % vs. 4.9 %; P < 0.001; Fig. 3). The
multivariable linear regression analysis showed that indepen-
dent determinants of FRS (adjustedR2 = 0.39, P < 0.001) were
thoracic aorta Na18F uptake (β = 0.37, P < 0.001) and thoracic
aorta CTcalcium burden (β = 0.42, P = 0.002), but not thorac-
ic aorta 18F-FDG uptake (β = 0.10, P = 0.113; Table 2, Fig. 4).
The agreement between mean calcium burden calculated on
CT images from 18F-FDG PET/CT and those calculated from
Na18F PET/CTwas considered excellent, as indicated by a small
interscan difference (Supplementary Figure 1). The results of our
study were similar when aortic tracer uptake was expressed as
FDG-TBRMAX/MEAN and NaF-TBRMAX/MEAN (Supplementary
Fig. 2, Supplementary Tables 5–7).
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Discussion
In this study, an increased risk of CVD, as estimated by the
FRS, was found to be associated with marked increases in
vascular calcification metabolism, as assessed by Na18F
PET/CT imaging, and vascular calcium burden, as assessed
by CT imaging, but was not associated with arterial inflam-
mation, as assessed by 18F-FDG PET/CT imaging. These
findings support the use of arterial Na18F PET/CT imaging
for identifying the vulnerable patient, but the value of arterial
18F-FDG PET/CT imaging is less clear.
Arterial inflammation and vascular calcification are
regarded as key processes in the pathogenesis of various
CVDs, in particular atherosclerosis [4, 5]. Atherosclerotic
plaque inflammation is characterized by accumulation of mac-
rophages, which are attracted to plaques in response to the
retention of lipids in the arterial intima [18]. Plaque macro-
phages secrete chemokines, proinflammatory cytokines and
matrix metalloproteinases, which contribute to a nonresolving
inflammatory response that leads to plaque hypoxia, plaque
necrosis, weakening of the protective fibrous cap and, ulti-
mately, plaque rupture [18, 19]. Plaque rupture is considered
Table 1 Subject demographics
Volunteers
(n =89)
Patients
(n =50)
P
value
Total
(N =139)
Age (years), mean ± SD 44 ± 14 57 ± 11 <0.001* 49 ± 14
Male sex, n (%) 47 (53) 25 (50) 0.860 72 (52)
Smokers, n (%)
Former 32 (36) 22 (44) 0.370 54 (39)
Current 3 (3) 10 (20) 0.002* 13 (9)
Family history, n (%) 16 (18) 19 (38) 0.014* 35 (25)
Blood pressure (mmHg), mean ± SD
Systolic 128 ± 17 131 ± 17 0.277 129 ± 17
Diastolic 77 ± 10 79 ± 8 0.105 78 ± 10
Body mass index (kg/m2), mean ± SD 27 ± 4 27 ± 4 0.291 27 ± 4
Cholesterol (mmol/L), mean ± SD
Total 4.9 ± 0.9 5.4 ± 0.9 0.006* 5.1 ± 0.9
LDL 3.1 ± 0.8 3.4 ± 0.9 0.037* 3.2 ± 0.8
HDL 1.4 ± 0.5 1.4 ± 0.4 0.834 1.4 ± 0.4
Triglycerides (mmol/L), mean ± SD 1.0 ± 0.7 1.2 ± 0.7 0.224 1.1 ± 0.7
Plasma glucose (mmol/L), mean ± SD 5.5 ± 0.5 5.9 ± 0.9 0.011* 5.6 ± 0.7
HbA1c (mmol/mol), mean ± SD 33.9 ± 4.1 37.4 ± 5.0 <0.001* 35.1 ± 4.7
eGFR (mL/min/1.73 m2), mean ± SD 82.9 ± 13.2 75.1 ± 14.3 0.002* 80.4 ± 14.1
Framingham risk score (%), median (25th, 75th
percentile)
4 (2, 9) 9 (6, 22) <0.001* 6 (2, 12)
Medication, n (%)
Statins 0 (0) 17 (35) <0.001* 17 (12)
Antihypertensive drugs 0 (0) 23 (46) <0.001* 23 (17)
Calcium burden
Thoracic aorta, n (%) 18 (20) 30 (60) <0.001* 48 (35)
Thoracic aorta (mm3), median (25th, 75th
percentile)
0 (0, 0) 1 (0, 5) <0.001* 0 (0, 1)
Injected dose (MBq), mean ± SD
18F-FDG 306 ± 59 315 ± 65 0.410 309 ± 61
18F-NaF 174 ± 39 175 ± 28 0.851 174 ± 35
Circulating time (min), mean ± SD
18F-FDG 181 ± 4 182 ± 5 0.500 181 ± 4
18F-NaF 92 ± 4 91 ± 4 0.339 91 ± 4
Radiotracer activity (kBq/mL), mean ± SDa
FDGMAX 8.79 ± 1.69 9.30 ± 1.95 0.085 8.97 ± 1.78
NaFMAX 3.36 ± 0.61 3.76 ± 0.76 <0.001* 3.50 ± 0.66
PET/CT system (%, 18F-FDG/Na18F)
GE Discovery STE 20/25 16/28 19/26
GE Discovery VCT 31/21 20/18 27/20
GE Discovery RX 25/32 32/20 27/27
GE Discovery 690/710 24/22 32/34 27/27
HbA1c Glycated haemoglobin, eGFR Estimated glomerular filtration rate
*P < 0.05
aActivity concentrations adjusted for blood activity, injected dose and PET/CT technology
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the most frequent cause of adverse cardiovascular events, such
as acute coronary syndromes and stroke [19, 20]. In response
to chronic inflammation and necrosis, atherosclerotic plaques
calcify [21]. It is believed that atherosclerotic plaque calcifi-
cation retards the inflammatory response, stabilizes the athero-
sclerotic plaque, and reduces the risk of plaque rupture.
Nonetheless, the earliest stages of plaque calcification are as-
sociated with increased plaque instability and an elevated risk
of rupture [22], whereas only advanced stages of plaque cal-
cification are associated with plaque stabilization [23]. A pos-
sible explanation for the increased risk of plaque rupture dur-
ing early stages of plaque calcification is that plaque
microcalcifications increase local tissue stress, which facilitate
plaque vulnerability [24]. Although plaque calcification is as-
sociated with plaque stabilization, the presence and degree of
vascular macrocalcifications is strongly predictive of adverse
cardiovascular events [7]. It appears that vascular calcifica-
tion, independent of its association with plaque stability, is a
marker of overall atherosclerotic disease burden, and thus, the
vulnerable patient [3, 25].
By inference, imaging techniques aimed at visualizing ar-
terial inflammation and vascular calcification are potent
markers of CVD risk. 18F-FDG PET/CT imaging can nonin-
vasively assess arterial inflammation, whereas Na18F PET/CT
and CT imaging can noninvasively assess vascular calcifica-
tion. 18F-FDG uptake reflects the rate of glycolysis, which is
particularly increased in atherosclerotic plaques that retain
macrophages [26] and plaques that undergo hypoxic stress
[27]. In addition to atherosclerotic plaque, aortic 18F-FDG
retention has been linked to formation of aneurysms and dis-
section of the aorta, which are diseases associated with inflam-
mation of the arterial media and arterial adventitia [28]. It has
a b c
Fig. 2 a Thoracic aorta 18F-FDG activity (FDGMAX) versus thoracic
aorta Na18F activity (NaFMAX). FDGMAX is not correlated with
NaFMAX (Spearman’s ρ = 0.07, P = 0.427). b FDGMAX versus thoracic
aorta CT calcium burden. FDGMAX is not correlated with thoracic aorta
CT calcium burden (Spearman’s ρ = 0.04, P = 0.654). c NaFMAX versus
thoracic aorta CT calcium burden. NaFMAX is positively correlated with
thoracic aorta CT calcium burden (Spearman’s ρ = 0.42, P < 0.001).
(FDGMAX and NaFMAX are the maximum activity concentrations of
18F-FDG and Na18F, respectively, adjusted for blood activity, injected
dose and PET/CT technology)
a b c
Fig. 3 The 10-year cardiovascular disease (CVD) risk estimated by the
Framingham risk score in relation to quartiles of (a) thoracic aorta 18F-
FDG activity (FDGMAX), (b) thoracic aorta Na
18F activity (NaFMAX),
and (c) thoracic aorta CT calcium burden. CVD risk is similar in all
quartiles of thoracic aorta FDGMAX, but increases linearly with each
increasing quartile of thoracic aorta NaFMAX (P < 0.001 for a linear trend)
and with each increasing quartile of thoracic aorta CT calcium burden
(P < 0.001 for a linear trend). s.e. standard error, m mean
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been reported that arterial 18F-FDG uptake increases in pro-
portion to CVD risk factors [29] and that aortic 18F-FDG
retention predicts adverse cardiovascular events beyond tradi-
tional CVD risk factors [6]. Na18F uptake reflects the active
exchange of hydroxyl groups of hydroxyapatite crystals for
fluoride producing fluorapatite [30]. This process is believed
to reflect calcification metabolism of osseous tissue, including
calcification of atherosclerotic plaque [31–33]. While calcifi-
cation of atherosclerotic plaque, which is regarded as a disease
of the arterial intima, arterial Na18F retention is believed to
also reflect calcification of the arterial media, a condition as-
sociated with arterial stiffening, increased pulse pressure, left
ventricular hypertrophy, and reduced myocardial perfusion
[34, 35]. Similar to arterial 18F-FDG retention, arterial Na18F
retention has also been reported to increase in proportion to
CVD risk factors [31, 32]. CT imaging targets structural vas-
cular calcifications. Numerous follow-up studies have shown
that the vascular calcium burden, as detected by CT imaging,
is a strong independent marker of CVD risk [7, 8].
This study confirmed the findings from previous investiga-
tions. First, this study confirmed that arterial 18F-FDG reten-
tion is not correlated with either arterial Na18F retention [10]
or CT calcium burden [9]. A previous study has shown that
18F-FDG-avid plaques rarely (∼7 %) accumulate Na18F and
only occasionally (∼15 %) colocate with structural calcium
deposits [9]. These findings suggest that arterial retention of
18F-FDG and Na18F represent different stages of the cardio-
vascular atherosclerotic disease process and their imaging
may help differentiate early from advanced stages of the dis-
ease [9] or may carry independent prognostic value. Second,
this study confirmed that arterial Na18F retention is positively
correlated with CT calcium burden [9]. A previous study has
shown that structural calcium deposits are present in approx-
imately 77 % of Na18F-avid plaques, whereas only 21 % of
vascular macrocalcifications retain Na18F [9]. These findings
suggest that arterial Na18F retention may discriminate active
from indolent vascular calcifications, associated with vulner-
able and stabilized plaques, respectively [10]. Our data seem
to confirm this suggestion. In those with CT calcium burden,
but below average aortic Na18F uptake, CVD risk was sub-
stantially lower compared to those with CT calcium burden
and above average aortic Na18F uptake (10.5 % vs. 17.5 %).
Lastly, this study confirmed that CVD risk, as estimated by the
FRS, increases linearly with increasing arterial Na18F uptake
and CT calcium burden [10, 36].
Despite confirming several findings from previous investi-
gations, our observations challenge the notion that arterial
inflammation, as assessed by 18F-FDG PET/CT, is associated
with an elevated risk of CVD [6]. There may be several ex-
planations for this discrepant finding. First, this study
a b c
Fig. 4 The 10-year cardiovascular disease (CVD) risk, estimated by the
Framingham risk score, in (a) subjects with below or above average
thoracic aorta 18F-FDG activity (FDGMAX) and Na
18F activity
(NaFMAX), (b) subjects with or without thoracic aorta CTcalcium burden
and below or above average FDGMAX, (c) subjects with or without tho-
racic aorta CT calcium burden and below or above average NaFMAX.
NaFMAX and thoracic aorta CT calcium burden differentiated subjects at
high and low CVD risk, whereas FDGMAX did not, m mean
Table 2 Multivariable linear
regression analysis of the
dependence of the 10-year car-
diovascular disease (CVD) risk,
estimated by the Framingham risk
score, on thoracic aorta 18F-FDG
activity (FDGMAX), thoracic aorta
Na18F activity (NaFMAX), and the
thoracic aorta CT calcium burden
(β standardized regression
coefficient)
Determinant Regression coefficient (95 % CI) β Adjusted R2 P
value
0.39 <0.001
Intercept (%) −9.46 (−16.70 to −3.75) 0.007
FDGMAX (kBq/mL) 0.50 (−0.08 to 1.15) 0.10 0.113
NaFMAX (kBq/mL) 5.37 (3.34 to 7.93) 0.37 <
0.001
CT calcium burden (mm3) 0.41 (0.26 to 1.07) 0.42 0.002
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evaluated subjects at low CVD risk (i.e. median FRS of 6 %),
whereas the majority of studies investigating arterial 18F-FDG
retention in relation to CVD risk evaluated subjects at high
CVD risk [6]. Therefore, our study might have detected early
stages of atherosclerotic plaque inflammation, but not lat-
er stages of inflammation that are associated with plaque
and patient vulnerability. Second, this study included sub-
jects with a broad age range, that is between 21 and
75 years. Therefore, it can be assumed that subjects with
a spectrum of atherosclerosis severity, ranging from mild
to severe disease were included. Both fatty streaks (the
hallmark of mild atherosclerosis) and high-risk vulnerable
plaques (the hallmark of severe atherosclerosis) are dense-
ly populated by macrophages [18]. Because 18F-FDG is
primarily retained in plaque macrophages [37–39], differ-
entiation of fatty streaks from high-risk vulnerable
plaques, and thus differentiation of mild from severe ath-
erosclerosis, may be difficult by 18F-FDG PET/CT. Third,
this study estimated CVD risk solely based on FRS. A
previous study has shown that aortic 18F-FDG retention
predicts CVD risk beyond FRS [6], and also demonstrated
that adding the aortic 18F-FDG retention index to FRS
results in a net reclassification improvement of approxi-
mately 25 % compared with FRS alone [6]. Because this
study estimated CVD risk solely via FRS, the incremental
value of arterial 18F-FDG retention over FRS in predicting
CVD risk could not be assessed. The three considerations
mentioned above may explain the lack of association be-
tween arterial 18F-FDG retention and CVD risk found in
this study.
Strengths and limitations
An important strength of the present study is that we prospec-
tively investigated the relationship between CVD risk and
arterial inflammation, vascular calcification metabolism, and
vascular calcium burden in a heterogeneous group of subjects
at low CVD risk. Previous studies that have investigated sim-
ilar relationships either were performed retrospectively in on-
cology patients [9] or involved exclusively elderly patients
with advanced CVD [10]. Such studies may be limited by
imaging protocols not necessarily optimized for imaging ar-
teries, by selection bias, or by both. In contrast, this study was
performed prospectively, included a heterogeneous group of
subjects at low CVD risk, and utilized imaging protocols op-
timized for artery imaging [13–15]. Thus we were able to
demonstrate that CVD risk is positively associated with in-
creases in thoracic aorta Na18F uptake and thoracic aortic
CT calcium burden, but is not associated with thoracic aorta
18F-FDG uptake.
The findings of this study, however, should be interpreted in
light of three limitations. First, CVD risk was estimated in terms
of the FRS. Although the revised FRS performs well in terms of
discrimination and calibration [12], it still tends to overestimate
risk in those at low CVD risk and underestimates risk in those at
high CVD risk. Our estimates of CVD risk may therefore be
inaccurate and there may be bias in the associations between
CVD risk and our imaging findings. However, because of the
cross-sectional nature of our study, we relied on an estimated
CVD risk. Second, the relationships between CVD risk and ar-
terial inflammation, vascular calcification metabolism, and vas-
cular calcium burdenwere evaluated in a cross-sectional study. A
previous study involving serial 18F-FDG PET/CT examinations
demonstrated that baseline arterial 18F-FDG uptake predicts the
finding of vascular calcium deposits on the follow-up examina-
tion, suggesting a temporal relationship between arterial inflam-
mation and vascular calcification [40]. Temporal relationships
are difficult to assess in cross-sectional studies and a longitudinal
approach is preferred for such an evaluation. Therefore, our find-
ing that arterial inflammation is not related either to vascular
calcification metabolism or to vascular calcium burden could
be attributed to our cross-sectional design. Third, ethical consid-
erations prevented collection of arterial specimens for histologi-
cal examination. Therefore, we could not relate our imaging
findings to the exact structure, biological composition and in-
flammatory state of the detected atherosclerotic plaques [9].
Substantiating arterial 18F-FDG and Na18F uptake by histopa-
thology, preferably in the early stages of the disease, might have
contributed to a better understanding of the metabolic pathways
that govern CVD risk.
Conclusion
Our findings indicate that an unfavourable cardiovascular risk
profile is associated with marked increases in thoracic aorta vas-
cular calcification metabolism and calcium burden, but not arte-
rial inflammation. Our findings support the use of arterial Na18F
PET/CT imaging for identifying the vulnerable patient, but the
value of arterial 18F-FDG PET/CT imaging is less clear.
Nonetheless, prospective long-term follow-up studies are re-
quired to assess the risk stratification abilities of arterial 18F-
FDG and Na18F PET/CT imaging beyond standard approaches,
such as the FRS and CT calcium score.
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